Please contact us for more information or to learn if you are eligible to participate.
To evaluate the effect of EFX compared to placebo on fibrosisregression in subjects with compensated cirrhosis due to NASH at Week 36
Fernando Membreno, MD
Akero Therapeutics, Inc.
Type of Trial